The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).
Mairead Geraldine McNamara
Other Remuneration - Pfizer
Lisa W Le
No relevant relationships to disclose
Anne M Horgan
No relevant relationships to disclose
Alex Aspinall
No relevant relationships to disclose
Kelly W Burak
No relevant relationships to disclose
Neesha C. Dhani
No relevant relationships to disclose
Eric Xueyu Chen
No relevant relationships to disclose
Mehrdad Sinaei
No relevant relationships to disclose
Glen Lo
No relevant relationships to disclose
Tae Kyoung Kim
No relevant relationships to disclose
Patrik Rogalla
No relevant relationships to disclose
Oliver F. Bathe
No relevant relationships to disclose
Jennifer J. Knox
Research Funding - Pfizer